Deciphera Pharmaceuticals (NASDAQ:DCPH) Sets New 12-Month High at $50.83

Share on StockTwits

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) shares reached a new 52-week high during trading on Tuesday . The company traded as high as $50.83 and last traded at $50.83, with a volume of 21240 shares changing hands. The stock had previously closed at $47.60.

Several brokerages have recently weighed in on DCPH. Piper Jaffray Companies set a $55.00 target price on Deciphera Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, September 30th. SunTrust Banks increased their price target on shares of Deciphera Pharmaceuticals to $60.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. HC Wainwright initiated coverage on shares of Deciphera Pharmaceuticals in a report on Thursday, October 3rd. They set a “buy” rating and a $60.00 price objective on the stock. JMP Securities boosted their price objective on shares of Deciphera Pharmaceuticals from $45.00 to $54.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 5th. Finally, Jefferies Financial Group began coverage on shares of Deciphera Pharmaceuticals in a report on Monday, September 30th. They issued a “buy” rating and a $47.00 target price for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the company. Deciphera Pharmaceuticals currently has an average rating of “Buy” and an average price target of $49.31.

The stock has a market cap of $2.41 billion, a PE ratio of -18.09 and a beta of 1.94. The business has a 50 day moving average of $43.16 and a 200-day moving average of $31.74.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings data on Monday, November 4th. The company reported ($1.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.19) by ($0.09). On average, sell-side analysts predict that Deciphera Pharmaceuticals Inc will post -4.25 earnings per share for the current fiscal year.

In related news, Director Michael Douglas Taylor sold 22,500 shares of the business’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $34.97, for a total value of $786,825.00. Also, CFO Thomas Patrick Kelly sold 11,250 shares of the business’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $34.97, for a total value of $393,412.50. In the last quarter, insiders sold 248,247 shares of company stock valued at $11,409,071. 7.02% of the stock is owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of Montreal Can acquired a new position in shares of Deciphera Pharmaceuticals in the second quarter valued at approximately $28,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Deciphera Pharmaceuticals by 162.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,737 shares of the company’s stock valued at $59,000 after buying an additional 1,074 shares during the last quarter. Tower Research Capital LLC TRC acquired a new position in Deciphera Pharmaceuticals in the 2nd quarter valued at $64,000. JPMorgan Chase & Co. increased its stake in Deciphera Pharmaceuticals by 89.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,057 shares of the company’s stock valued at $95,000 after buying an additional 1,913 shares during the period. Finally, Morgan Stanley raised its position in Deciphera Pharmaceuticals by 214.8% during the 2nd quarter. Morgan Stanley now owns 7,864 shares of the company’s stock worth $177,000 after buying an additional 5,366 shares during the last quarter. 69.45% of the stock is owned by hedge funds and other institutional investors.

About Deciphera Pharmaceuticals (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Featured Article: What is a Futures Contract?

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.